Contribution of neuromuscular disorders to nonimmune hydrops fetalis diagnosed by exome sequencing: A meta-analysis and systematic literature review

ACMG 2026

Mar 10, 2026
Hereditary
Presentation

Stephanie Rice, Mona Makhamreh, Kavya Shivashankar, Leshae Cenac, Seth Berger, Huda Al-Kouatly

Introduction
Neuromuscular disorders (NMD) affect 1 in 3000 live births and are increasingly recognized in association with nonimmune hydrops fetalis (NIHF). Our objective was to assess the monogenic contribution of NMD to NIHF and review the pooled exome sequencing (ES) diagnostic yield of NMD in NIHF.

 

Methods
A systematic review and meta-analysis of prenatal ES studies for NIHF was conducted between 1/1/2000-08/1/2024. This study was registered under the PROSPERO identification number CRD42023396814. Hydrops was defined as fluid collection in at least two fetal compartments which includes: skin edema, ascites, pleural effusion, and/or pericardial effusion. All NIHF cases with variants identified in genes included on NMD gene panels or genes with a neuromuscular phenotype were included. Genetic variants were curated based on current American College of Medical Genetics and Genomics guidelines. “Pathogenic” or “likely pathogenic” variants were considered diagnostic. “Variants of uncertain significance” (VUS) were also reported. Additional characteristics such as family history, inheritance, consanguinity, pregnancy outcomes, and whether the NIHF was isolated or non-isolated were also recorded. Isolated NIHF was defined when major structural malformations or growth abnormalities were not prenatally diagnosed. Statistical heterogeneity was evaluated using Higgins’ I2 statistic. A random-effects meta-analysis of proportions was conducted using the metaprop function in the meta-R package. Study-specific proportions were pooled, and 95% confidence intervals (CI) were calculated.

 

Results
In 41 studies that met the inclusion criteria, ES confirmed a molecular diagnosis of NMD in 24% (50/212) of NIHF cases with a genetic diagnosis and 9% (50/564) of total NIHF cases. The pooled diagnostic yield of NMD in NIHF cases diagnosed by ES is 17% (95% CI: 9–26%; I2 = 24%). Among all NIHF cases, 5% (95% CI: 2–9%; I2 = 37.5%) were attributed to NMD. Eight additional cases had NMD-associated VUS. Diagnostic variants were identified in a total of 25 NMD genes. The most prevalent genes were RAPSN in 16% (8/50) of diagnosed cases and RYR1 in 10% (5/50), followed by ASCC1 and NEB each in 8% (4/50, 8%) of cases. ACTA1, BICD2, and MUSK were each implicated in 6% (3/50) of diagnosed cases, while DOK7 and GBE1 were each in 4% (2/50). The remaining 16 genes were only reported once (1/50, 2%) which include: ACAD9, AGRN, ATAD3A, CHRNG, FKTN, GLDN, HSPB1, ITPR1, KLHL40, MAGEL2, MYH3, MYH7, SCN4A, SDHA, TAZ, and ZNF148. Of the diagnosed NMD cases, 32% (16/50) had isolated NIHF while 68% (34/50) were non-isolated, with two-thirds (23/34) presenting with joint contractures. Of the cases that reported additional characteristics, 61% (20/33) were recurrent and 37% (12/33) were in consanguineous families. Diagnostic variants in autosomal dominant genes were reported in 28% of cases (14/50), while 70% (35/50) were in autosomal recessive genes. One case (1/50, 2%) had a diagnostic variant in the X-linked recessive gene, TAZ. Pregnancy outcomes were reported in 28 cases: 43% (12/28) resulted in a fetal death, 43% (12/28) had termination of pregnancy, and 11% (3/28) resulted in neonatal deaths. One case (1/28, 4%) resulted in a live birth.

 

Conclusion
NMD account for nearly one-fourth of all genetically diagnosed NIHF cases, representing a major monogenic etiology of NIHF. Most affected fetuses have non-isolated hydrops presentation and poor perinatal outcome. Accurate identification of an underlying NMD is essential to support timely genetic counseling, address the high recurrence risks, and guide informed reproductive decision-making.